S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
The Real Reason They Murdered JFK? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
The Real Reason They Murdered JFK? (Ad)
How major US stock indexes fared Friday, 9/29/2023
MarketBeat Week in Review – 9/25 - 9/29
This Stock Could Go Up 66% or More. (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
The Real Reason They Murdered JFK? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
The Real Reason They Murdered JFK? (Ad)
How major US stock indexes fared Friday, 9/29/2023
MarketBeat Week in Review – 9/25 - 9/29
This Stock Could Go Up 66% or More. (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
The Real Reason They Murdered JFK? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
The Real Reason They Murdered JFK? (Ad)
How major US stock indexes fared Friday, 9/29/2023
MarketBeat Week in Review – 9/25 - 9/29
This Stock Could Go Up 66% or More. (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
The Real Reason They Murdered JFK? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
The Real Reason They Murdered JFK? (Ad)
How major US stock indexes fared Friday, 9/29/2023
MarketBeat Week in Review – 9/25 - 9/29
This Stock Could Go Up 66% or More. (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
NASDAQ:YMAB

Y-mAbs Therapeutics (YMAB) Stock Forecast, Price & News

$5.45
-0.13 (-2.33%)
(As of 09/29/2023 ET)
Compare
Today's Range
$5.36
$5.86
50-Day Range
$4.86
$6.29
52-Week Range
$2.70
$15.89
Volume
270,849 shs
Average Volume
129,813 shs
Market Capitalization
$237.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.63

Y-mAbs Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.18 Rating Score
Upside/​Downside
131.7% Upside
$12.63 Price Target
Short Interest
Bearish
8.39% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.41mentions of Y-mAbs Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.64) to ($0.51) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.78 out of 5 stars

Medical Sector

813th out of 970 stocks

Pharmaceutical Preparations Industry

384th out of 450 stocks


YMAB stock logo

About Y-mAbs Therapeutics (NASDAQ:YMAB) Stock

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody which has completed pivotal phase 2 clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, and Omburtamab 03-133 that is in phase 1 clinical trials for the treatment of intrathecal immunotherapy for CNS/leptomeningeal metastases. In addition, its product pipeline includes huB7-H3 for the treatment of systemic solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

YMAB Price History

YMAB Stock News Headlines

The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
4 Analysts Have This to Say About Y-mAbs Therapeutics
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Y-mAbs Therapeutics earnings: here's what Wall Street expects
Y-mAbs to Participate at Upcoming Investor Conferences
Analyst Expectations for Y-mAbs Therapeutics's Future
See More Headlines
Receive YMAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Y-mAbs Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

YMAB Company Calendar

Last Earnings
8/10/2023
Today
9/30/2023
Next Earnings (Estimated)
11/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:YMAB
Fax
N/A
Employees
147
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$12.63
High Stock Price Forecast
$22.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+131.7%
Consensus Rating
Hold
Rating Score (0-4)
2.18
Research Coverage
11 Analysts

Profitability

Net Income
$-95,570,000.00
Pretax Margin
-45.75%

Debt

Sales & Book Value

Annual Sales
$65.27 million
Book Value
$2.50 per share

Miscellaneous

Free Float
34,242,000
Market Cap
$237.73 million
Optionable
Not Optionable
Beta
0.71
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Thomas Gad (Age 53)
    Founder, Interim CEO, Pres, Head of Bus. Devel. & Strategy and Director
    Comp: $1.05M
  • Mr. Bo Kruse (Age 51)
    Exec. VP, Sec., Treasurer & CFO
    Comp: $685.02k
  • Ms. Susan Smith (Age 52)
    Sr. VP & Chief Commercial Officer
    Comp: $710k
  • Mr. Joris Wiel Jan Wilms (Age 49)
    Sr. VP & COO
  • Dr. Torben Lund-Hansen M.Sc. (Age 72)
    Ph.D., Sr. VP & CTO
  • Dr. Steen Lisby M.D. (Age 59)
    M.Sc., Sr. VP & Chief Scientific Officer
  • Dr. Vignesh Rajah M.B.A. (Age 58)
    MBBS, Sr. VP & Chief Medical Officer













YMAB Stock - Frequently Asked Questions

Should I buy or sell Y-mAbs Therapeutics stock right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Y-mAbs Therapeutics in the last year. There are currently 2 sell ratings, 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" YMAB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in YMAB, but not buy additional shares or sell existing shares.
View YMAB analyst ratings
or view top-rated stocks.

What is Y-mAbs Therapeutics' stock price forecast for 2023?

11 Wall Street research analysts have issued 1 year target prices for Y-mAbs Therapeutics' stock. Their YMAB share price forecasts range from $5.00 to $22.00. On average, they predict the company's stock price to reach $12.63 in the next twelve months. This suggests a possible upside of 131.7% from the stock's current price.
View analysts price targets for YMAB
or view top-rated stocks among Wall Street analysts.

How have YMAB shares performed in 2023?

Y-mAbs Therapeutics' stock was trading at $4.88 at the beginning of the year. Since then, YMAB shares have increased by 11.7% and is now trading at $5.45.
View the best growth stocks for 2023 here
.

When is Y-mAbs Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our YMAB earnings forecast
.

How were Y-mAbs Therapeutics' earnings last quarter?

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) issued its quarterly earnings data on Thursday, August, 10th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.10. The business had revenue of $20.75 million for the quarter, compared to analysts' expectations of $19.04 million. Y-mAbs Therapeutics had a negative net margin of 45.96% and a negative trailing twelve-month return on equity of 36.37%.

What guidance has Y-mAbs Therapeutics issued on next quarter's earnings?

Y-mAbs Therapeutics updated its FY 2023 earnings guidance on Thursday, August, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $80.00 million-$85.00 million, compared to the consensus revenue estimate of $82.79 million.

What other stocks do shareholders of Y-mAbs Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Y-mAbs Therapeutics investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Corbus Pharmaceuticals (CRBP), CTI BioPharma (CTIC), Nabriva Therapeutics (NBRV), Occidental Petroleum (OXY), VBI Vaccines (VBIV), Vaxart (VXRT) and Amarin (AMRN).

When did Y-mAbs Therapeutics IPO?

(YMAB) raised $80 million in an initial public offering (IPO) on Friday, September 21st 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity acted as the underwriters for the IPO and BTIG was co-manager.

What is Y-mAbs Therapeutics' stock symbol?

Y-mAbs Therapeutics trades on the NASDAQ under the ticker symbol "YMAB."

How do I buy shares of Y-mAbs Therapeutics?

Shares of YMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Y-mAbs Therapeutics' stock price today?

One share of YMAB stock can currently be purchased for approximately $5.45.

How much money does Y-mAbs Therapeutics make?

Y-mAbs Therapeutics (NASDAQ:YMAB) has a market capitalization of $237.73 million and generates $65.27 million in revenue each year. The company earns $-95,570,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis.

How many employees does Y-mAbs Therapeutics have?

The company employs 147 workers across the globe.

How can I contact Y-mAbs Therapeutics?

Y-mAbs Therapeutics' mailing address is 230 Park Avenue Suite 3350, NEW YORK NY, 10169. The official website for the company is www.ymabs.com. The company can be reached via phone at (646) 885-8505 or via email at info@ymabs.com.

This page (NASDAQ:YMAB) was last updated on 9/30/2023 by MarketBeat.com Staff

My Account -